NEW YORK (GenomeWeb) – Indi Molecular this week announced a co-development deal with Sigma-Aldrich to explore use of its PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of protein research reagents.

Despite the deal, though, Indi Molecular has shifted its focus from developing PCCs as research and diagnostic tools to therapeutics, CEO Albert Luderer told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.